Additionally, our results showed a unique subcellular compartmentalization of PKM2 in NSCLC cells and xenografts upon treating them with anti-PKM2 therapies in vitro and in vivo indicating that PKM2 expression may serve as a biomarker of therapeutic response in NSCLC. This evidence concerns the gene PKM and non-small cell lung carcinoma.